GT Biopharma, Inc. (NASDAQ: GTBP) is a clinical stage immuno-oncology company focused on developing innovative therapies based on the Company's proprietary NK cell engager (TriKE®) technology. TriKE® therapeutic agents are targeted immunotherapeutic agents that simultaneously react with natural killer (NK) cells and cancer cells to selectively facilitate the killing of cancer cells.
GT Biopharma Appoints New Member to its Board of Directors
May 14, 2025 • 7:00 EDT | Read More
GT Biopharma to Participate in the 10th Anniversary of the Innate Killer Summit
Mar 4, 2025 • 7:00 EST | Read More
Change
Volume
52 Week Range
